The DOI matches its Crossref record; 187 of the 187 references it cites were found in a registry or an index.
Diabetes and cancer
Open accessAbstract
Diabetes and cancer are two heterogeneous, multifactorial, severe, and chronic diseases. Because of their frequency, reciprocal influences - even minor influences - may have a major impact. Epidemiological studies clearly indicate that the risk of several types of cancer (including pancreas, liver, breast, colorectal, urinary tract, and female reproductive organs) is increased in diabetic patients. Mortality is also moderately increased. Several confounding factors, having general or site-specific relevance, make it difficult to accurately assess cancer risk in diabetic patients. These factors include diabetes duration, varying levels of metabolic control, different drugs used for therapy, and the possible presence of chronic complications. Hyperinsulinemia most likely favors cancer in diabetic patients as insulin is a growth factor with pre-eminent metabolic but also mitogenic effects, and its action in malignant cells is favored by mechanisms acting at both the receptor and post-receptor level. Obesity, hyperglycemia, and increased oxidative stress may also contribute to increased cancer risk in diabetes. While anti-diabetic drugs have a minor influence on cancer risk (except perhaps the biguanide metformin that apparently reduces the risk), drugs used to treat cancer may either cause diabetes or worsen a pre-existing diabetes. In addition to the well-known diabetogenic effect of glucocorticoids and anti-androgens, an increasing number of targeted anti-cancer molecules may interfere with glucose metabolism acting at different levels on the signaling substrates shared by IGF-I and insulin receptors. In conclusion, diabetes and cancer have a complex relationship that requires more clinical attention and better-designed studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Diabetes is associated with reduced risk of prostate cancer.”
From Diabetes and Cancer (2010) · cites this paper as [6]
In the citing paper
“Diabetes (primarily type 2) is associated with increased risk for some cancers (liver, pancreas, endometrium, colon and rectum, breast, bladder).”
From Diabetes and Cancer (2010) · cites this paper as [6]
In the citing paper
“Epidemiologic evidence suggests that people with diabetes are at significantly higher risk for many forms of cancer.”
From Diabetes and Cancer (2010) · cites this paper as [6]
In the citing paper
“For some other cancer sites there appears to be no association or the evidence is inconclusive.”
From Diabetes and Cancer (2010) · cites this paper as [6]
In the citing paper
“Other cancers (e.g., lung) do not appear to be associated with an increased risk in diabetes, and the evidence for others (e.g., kidney, non-Hodgkin lymphoma) is inconclusive.”
From Diabetes and Cancer (2010) · cites this paper as [6]
In the citing paper
“The relative risks imparted by diabetes are greatest (about twofold or higher) for cancers of the liver, pancreas, and endometrium, and lesser (about 1.2–1.5 fold) for cancers of the colon and rectum, breast, and bladder.”
From Diabetes and Cancer (2010) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
Hoskins, R. G. (1953) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-13-4-473 · Cited by 3,780
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(1911) · JAMA · doi:10.1001/jama.1911.04260070032017 · Cited by 3,355
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
The American Journal of Gastroenterology
(2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.80003397.x · Cited by 2,202
Insulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059
Archives of Biochemistry and Biophysics
Carter, H. E., Bhattacharyya, P., Weidman, K. R., & Fraenkel, G. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1981.tb06727.x · Cited by 1,895
Flagged first, then by citations
Research works printed but not linked: 1
- Lindblad P Adami HO 2002 Kidney cancer. In Textbook of Cancer Epidemiology, pp 467–485 Eds HunterDAdamiHOTrichopoulosD. New York: Oxford University Press.
Cited by
Sorted by citations
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
Economic Costs of Diabetes in the U.S. in 2012
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc12-2625 · Cited by 2,227
Diabetes and Cancer: A Consensus Report
Giovannucci, E. L., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20078 · Cited by 1,082
Molecular mechanisms of cancer development in obesity
Khandekar, M. J., Cohen, P., & Spiegelman, B. M. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3174 · Cited by 921
Obesity and cancer—mechanisms underlying tumour progression and recurrence
Park, J., Morley, T. S., Kim, M. G., Clegg, D. J., & Scherer, P. E. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.94 · Cited by 813
Giri, B., Dey, S., Das, T., Sarkar, M., Banerjee, J., & Dash, S. K. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.07.157 · Cited by 706
Insulin resistance and cancer risk: An overview of the pathogenetic mechanisms
Arcidiacono, B., Iiritano, S., Nocera, A., Possidente, K., Nevolo, M. T., Ventura, V., Foti, D., Chiefari, E., & Brunetti, A. (2012) · Experimental Diabetes Research · doi:10.1155/2012/789174 · Cited by 606
Metformin in Cancer Treatment and Prevention
Morales, D. R., & Morris, A. D. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-062613-093128 · Cited by 494
Wilding, J. P. H., Woo, V., Soler, N. G., Pahor, A., Sugg, J., Rohwedder, K., Parikh, S., & for the Dapagliflozin 006 Study Group* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-6-201203200-00003 · Cited by 478
Cancer statistics for Hispanics/Latinos, 2015
Siegel, R. L., Fedewa, S. A., Miller, K. D., Sauer, A. G., Pinheiro, P. S., Martinez‐Tyson, D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21314 · Cited by 474
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
“…and sitagliptin apparently significantly reduced the odds ratios of some special cancers, such as lung cancer, prostate cancer, lymphoma/multiple myeloma for exenatide, and colon cancer and prostate cancer for sitagliptin (Vigneri et al., 2009; Koehler et al., 2011; Nauck and Friedrich, 2013).”
BackgroundEpidemiology of prostate cancer in Asian countries
Kimura, T., & Egawa, S. (2018) · International Journal of Urology · doi:10.1111/iju.13593 · Cited by 413
Mortality After Incident Cancer in People With and Without Type 2 Diabetes
Currie, C. J., Poole, C., Jenkins‐Jones, S., Gale, E. A., Johnson, J. A., & Morgan, C. L. (2012) · Diabetes Care · doi:10.2337/dc11-1313 · Cited by 398
The proliferating role of insulin and insulin-like growth factors in cancer
Gallagher, E. J., & LeRoith, D. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.06.007 · Cited by 398
Insulin Receptor Isoforms in Physiology and Disease: An Updated View
Belfiore, A., Malaguarnera, R., Vella, V., Lawrence, M. C., Sciacca, L., Frasca, F., Morrione, A., & Vigneri, R. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00073 · Cited by 390
Is Diabetes Mellitus an Independent Risk Factor for Colon Cancer and Rectal Cancer?
Yuhara, H., Steinmaus, C., Cohen, S. E., Corley, D. A., Tei, Y., & Buffler, P. A. (2011) · The American Journal of Gastroenterology · doi:10.1038/ajg.2011.301 · Cited by 374
Review: Diabetes, Obesity, and Cancer—Pathophysiology and Clinical Implications
Lega, I. C., & Lipscombe, L. L. (2019) · Endocrine Reviews · doi:10.1210/endrev/bnz014 · Cited by 381
“Cancers most commonly associated with diabetes are those of the pancreas, liver, endometrium, breast, colon, and bladder, while notably, prostate cancer has an inverse association with diabetes (2).”
Hyperglycemia as a Risk Factor for Cancer Progression
Ryu, T. Y., Park, J., & Scherer, P. E. (2014) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2014.38.5.330 · Cited by 331
Alam, S., Hasan, M. K., Neaz, S., Hussain, N., Hossain, M. F., & Rahman, T. (2021) · Diabetology · doi:10.3390/diabetology2020004 · Cited by 384
“Diabetic CHC patients have an augmented risk of progression of cirrhosis and hepatocellular carcinoma [84,85].”
BackgroundCommon risk factors for heart failure and cancer
Meijers, W. C., & de Boer, R. A. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz035 · Cited by 331
Diagnosis of obesity and use of obesity biomarkers in science and clinical medicine
Nimptsch, K., Konigorski, S., & Pischon, T. (2018) · Metabolism · doi:10.1016/j.metabol.2018.12.006 · Cited by 333
Hyperinsulinemia in Obesity, Inflammation, and Cancer
Zhang, A. M. Y., Wellberg, E. A., Kopp, J. L., & Johnson, J. D. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0250 · Cited by 344
“Retrospective studies show that metformin, which reduces hyperinsulinemia, may lower pancreatic cancer risk in animals [292] and in patients by up to 60% [182,293-297], although the magnitude of this effect is controversial [298,299] and it is unclear whether metformin acts via lowering insulin or modulating AMP-activ…”
BackgroundMetformin Amplifies Chemotherapy-Induced AMPK Activation and Antitumoral Growth
Rocha, G. Z., Dias, M. M., Ropelle, E. R., Osório–Costa, F., Rossato, F. A., Vercesi, A. E., Saad, M. J. A., & Carvalheira, J. B. C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2243 · Cited by 315
Metformin: Multi-faceted protection against cancer
Barco, S. D., Vázquez‐Martín, A., Cufí, S., Oliveras‐Ferraros, C., Bosch‐Barrera, J., Joven, J., Martı́n-Castillo, B., & Menéndez, J. A. (2011) · Oncotarget · doi:10.18632/oncotarget.387 · Cited by 307
Obesity, type 2 diabetes, and cancer: the insulin and IGF connection
Cohen, D., & LeRoith, D. (2012) · Endocrine Related Cancer · doi:10.1530/erc-11-0374 · Cited by 308
Evaluating All Potential Oral Complications of Diabetes Mellitus
Verhulst, M. J. L., Loos, B. G., Gerdes, V. E. A., & Teeuw, W. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00056 · Cited by 294
“Relationship With Diabetes Mellitus: Epidemiology Patients with DM have an increased risk for developing cancer in several organs and tissues, as well as an increase in cancer mortality, compared to subjects without DM (316).”
BackgroundDiabetes and cancer: two diseases with obesity as a common risk factor
Garg, S. K., Maurer, H., Reed, K., & SELAGAMSETTY, R. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12124 · Cited by 281
Belfiore, A., & Malaguarnera, R. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0074 · Cited by 272
Cancer in kidney transplant recipients
Au, E. H. K., Wong, G., & Chapman, J. R. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0022-6 · Cited by 271
Johnson, J. A., Carstensen, B., Witte, D. R., Bowker, S. L., Lipscombe, L. L., & Renehan, A. G. (2012) · Diabetologia · doi:10.1007/s00125-012-2525-1 · Cited by 262
Pierotti, M. A., Berrino, F., Gariboldi, M., Melani, C. C., Mogavero, A., Negri, T., Pasanisi, P., & Pilotti, S. (2012) · Oncogene · doi:10.1038/onc.2012.181 · Cited by 253
Diabetes mellitus and cancer risk: Review of the epidemiological evidence
Shikata, K., Ninomiya, T., & Kiyohara, Y. (2012) · Cancer Science · doi:10.1111/cas.12043 · Cited by 247
Risk Evaluation of cAncers in Chinese diabeTic Individuals: A lONgitudinal (REACTION) study
Ning, G., & The REACTION Study Group (2012) · Journal of Diabetes · doi:10.1111/j.1753-0407.2012.00182.x · Cited by 240
Patterson, R. E., Cadmus, L. A., Emond, J. A., & Pierce, J. P. (2010) · Maturitas · doi:10.1016/j.maturitas.2010.01.004 · Cited by 246
Hyperglycemia, a Neglected Factor during Cancer Progression
Duan, W., Shen, X., Lei, J., Xu, Q., Yu, Y., Li, R., Wu, E., & Ma, Q. (2014) · BioMed Research International · doi:10.1155/2014/461917 · Cited by 242
Insulin resistance and hyperinsulinaemia in the development and progression of cancer
Godsland, I. F. (2009) · Clinical Science · doi:10.1042/cs20090399 · Cited by 233
Cancer incidence in Spain, 2015
REDECAN Working Group, Galcerán, J., Ameijide, A., Carulla, M., Mateos, A., Quirós, J. R., Rojas, D., Alemán, A., Torrella, A., Chico, M. G. G., et al. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1607-9 · Cited by 247
Diabetes, Obesity, and Breast Cancer
Kang, C., LeRoith, D., & Gallagher, E. J. (2018) · Endocrinology · doi:10.1210/en.2018-00574 · Cited by 232
Insulin, insulin receptors, and cancer
Vigneri, R., Goldfine, I. D., & Frittitta, L. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0508-7 · Cited by 224
Chen, Y., Wu, F., Saito, E., Lin, Y., Song, M., Luu, H. N., Gupta, P. C., Sawada, N., Tamakoshi, A., Shu, X., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4229-z · Cited by 207
Diabetes Mellitus as a Risk Factor for Open-Angle Glaucoma: A Systematic Review and Meta-Analysis
Zhou, M., Wang, W., Huang, W., & Zhang, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102972 · Cited by 204
Chronic Diabetes Complications: The Need to Move beyond Classical Concepts
Mauricio, D., Alonso, N., & Gratacòs, M. (2020) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2020.01.007 · Cited by 210
Singh, P., Alex, J. M., & Bast, F. (2013) · Medical Oncology · doi:10.1007/s12032-013-0805-3 · Cited by 208
Deng, L., Gui, Z., Zhao, L., Wang, J., & Shen, L. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2055-1 · Cited by 202
Chen, G., Xu, S., Renko, K., & Derwahl, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1754 · Cited by 196
Chang, C., Lin, J., Wu, L., Lai, M., Chuang, L., & Chan, K. A. (2011) · Hepatology · doi:10.1002/hep.25509 · Cited by 193
PGC1α Promotes Tumor Growth by Inducing Gene Expression Programs Supporting Lipogenesis
Bhalla, K., Hwang, B. J., Dewi, R. E., Ou, L., Twaddel, W., Fang, H., Vafai, S. B., Vazquez, F., Puigserver, P., Boros, L. G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1011 · Cited by 195
The Warburg Effect Revisited—Lesson from the Sertoli Cell
Oliveira, P. F., Martins, A. D., Moreira, A. C., Cheng, C. Y., & Alves, M. G. (2014) · Medicinal Research Reviews · doi:10.1002/med.21325 · Cited by 193
Hyperglycemia, tumorigenesis, and chronic inflammation
Chang, S., & Yang, W. V. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.11.003 · Cited by 197
Effects of hyperglycemia on the progression of tumor diseases
Li, W., Zhang, X., Sang, H., Zhou, Y., Shang, C., Wang, Y., & Zhu, H. Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1309-6 · Cited by 188
Thakkar, B., Aronis, K. N., Vamvini, M. T., Shields, K. S., & Mantzoros, C. S. (2013) · Metabolism · doi:10.1016/j.metabol.2013.01.014 · Cited by 188
Bi, Y., Lu, J., Wang, W., Mu, Y., Zhao, J., Liu, C., Chen, L., Shi, L., Li, Q., Wan, Q., et al. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12108 · Cited by 187
on behalf of the Diabetes and Cancer Research Consortium, Carstensen, B., Read, S. H., Friis, S., Sund, R., Keskimäki, I., Svensson, A.-M., Ljung, R., Wild, S. H., Kerssens, J. J., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-3884-9 · Cited by 180
Algire, C., Amrein, L., Bazile, M., David, S., Zakikhani, M., & Pollak, M. (2010) · Oncogene · doi:10.1038/onc.2010.483 · Cited by 186
Risk of Cancer Following Hospitalization for Type 2 Diabetes
Hemminki, K., Li, X., Sundquist, J., & Sundquist, K. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0300 · Cited by 180
Goodwin, P. J., Stambolic, V., Lemieux, J., Chen, B. E., Parulekar, W. R., Gelmon, K. A., Hershman, D. L., Hobday, T. J., Ligibel, J. A., Mayer, I. A., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1224-1 · Cited by 178
“Both type 2 diabetes and hyperinsulinemia have been associated with increased breast cancer risk in epidemiologic studies [ 18 ].”
BackgroundGenetics of type 2 diabetes: pathophysiologic and clinical relevance
Herder, C., & Roden, M. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02454.x · Cited by 187
From obesity to diabetes and cancer: epidemiological links and role of therapies
García‐Jiménez, C., Gutiérrez‐Salmerón, M. T., Chocarro‐Calvo, A., García-Martínez, J. M., Castaño, Á., & la Vieja, A. D. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.37 · Cited by 173
Johnson, J. A., Bowker, S. L., Richardson, K., & Marra, C. A. (2011) · Diabetologia · doi:10.1007/s00125-011-2242-1 · Cited by 168
“The risk of endometrial cancer appears to be doubled in women with diabetes [1, 2].”
BackgroundResultInfluentialPrevalence of Diabetes Mellitus in Pancreatic Cancer Compared to Common Cancers
Aggarwal, G., Kamada, P., & Chari, S. T. (2013) · Pancreas · doi:10.1097/mpa.0b013e3182592c96 · Cited by 167
The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression
Rose, D. P., & Vona-Davis, L. C. (2012) · Endocrine Related Cancer · doi:10.1530/erc-12-0203 · Cited by 175
Animal models for type 1 and type 2 diabetes: advantages and limitations
Singh, R. K., Gholipourmalekabadi, M., & Shafikhani, S. H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1359685 · Cited by 188
“In addition, diabetes has also been associated with increased risk of certain cancers and is a recognized risk factor for mental disorders, such as Alzheimer ’ s disease (6, 7).”
BackgroundMetformin: An anti-diabetic drug to fight cancer
Daugan, M. V., Wojcicki, A. D., d’Hayer, B., & Boudy, V. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.10.006 · Cited by 172
Han, L., Ma, Q., Li, J., Liu, H., Li, W., Ma, G., Xu, Q., Zhou, S. Y., & Wu, E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027074 · Cited by 162
Incidence of Diabetes After Cancer Development
Hwangbo, Y., Kang, D., Kang, M., Kim, S., Lee, E. K., Kim, Y. A., Chang, Y. J., Choi, K. S., Jung, S., Woo, S. M., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1684 · Cited by 163
Diabetes and cancer: Epidemiological and biological links
Wang, M., Yang, Y., & Liao, Z. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i6.227 · Cited by 158
Rizos, C. V., & Elisaf, M. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.02.038 · Cited by 155
The effect of environmental chemicals on the tumor microenvironment
Casey, S. C., Vaccari, M., Al‐Mulla, F., Al-Temaimi, R. A., Amedei, A., Barcellos‐Hoff, M. H., Brown, D. G., Chapellier, M., Christopher, J., Curran, C. S., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv035 · Cited by 159
“In particular, subjects with type 2 diabetes mellitus are at increased risk of a wide range of malignancies, including breast, endometrial, bladder, kidney, colorectal, pancreatic and liver cancer, as well as hematologic malignancies such as non-Hodgkin’s lymphoma (132), whereas the risk of prostate cancer is reduced…”
BackgroundGarrett, C. R., Hassabo, H. M., Bhadkamkar, N. A., Wen, S., Baladandayuthapani, V., Kee, B. K., Eng, C., & Hassan, M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.71 · Cited by 153
Metformin and cancer: An existing drug for cancer prevention and therapy (Review)
Zi, F., Zi, H., Li, Y., He, J., Shi, Q., & Cai, Z. (2017) · Oncology Letters · doi:10.3892/ol.2017.7412 · Cited by 156
New Perspective for an Old Antidiabetic Drug: Metformin as Anticancer Agent
Leone, A., Gennaro, E. D., Bruzzese, F., Avallone, A., & Budillon, A. (2013) · Cancer treatment and research · doi:10.1007/978-3-642-38007-5_21 · Cited by 150
“However, insulin alone is insufficient to promote cancer progression because the pancreatic cells in type 1 diabetic patients are not exposed to increased insulin levels compared to other tissues [64, 80].”
BackgroundInfluentialMalaguarnera, R., Frasca, F., Garozzo, A., Gianì, F., Pandini, G., Vella, V., Vigneri, R., & Belfiore, A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1255 · Cited by 150
Marinac, C. R., Sears, D. D., Natarajan, L., Gallo, L. C., Breen, C. I., & Patterson, R. E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136240 · Cited by 144
Diabetes and cancer: Pathophysiological fundamentals of a ‘dangerous affair’
Cignarelli, A., Genchi, V. A., Caruso, I., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.04.002 · Cited by 156
Campbell, P. T., Deka, A., Jacobs, E. J., Newton, C. C., Hildebrand, J. S., McCullough, M. L., Limburg, P. J., & Gapstur, S. M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.06.072 · Cited by 147
Methylglyoxal, a potent inducer of AGEs, connects between diabetes and cancer
Bellier, J., Nokin, M., Lardé, E., Karoyan, P., Peulen, O., Castronovo, V., & Bellahcène, A. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.01.002 · Cited by 143
Vitamin B6 and Diabetes: Relationship and Molecular Mechanisms
Mascolo, E., & Vernı̀, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103669 · Cited by 148
Challenges and Perspectives in the Treatment of Diabetes Associated Breast Cancer
Samuel, S. M., Varghese, E., Varghese, S., & Büsselberg, D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.08.004 · Cited by 141
Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling
Sciacca, L., Cassarino, M. F., Genua, M., Pandini, G., Moli, R. L., Squatrito, S., & Vigneri, R. (2010) · Diabetologia · doi:10.1007/s00125-010-1760-6 · Cited by 142
Diabetes and cancer: A comprehensive review
Abudawood, M. (2019) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_242_19 · Cited by 146
Rau, H.-H., Hsu, C., Lin, Y.-A., Atique, S., Fuad, A., Wei, L., & Hsu, M. (2015) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2015.11.009 · Cited by 140
“[9] P.”
BackgroundEuropean Code against Cancer 4th Edition: Obesity, body fatness and cancer
Anderson, A. S., Key, T. J., Norat, T., Scoccianti, C., Cecchini, M., Berrino, F., Boutron‐Ruault, M., Espina, C., Leitzmann, M. F., Powers, H. J., et al. (2015) · Cancer Epidemiology · doi:10.1016/j.canep.2015.01.017 · Cited by 144
Mortality Trends Among People With Type 1 and Type 2 Diabetes in Australia: 1997–2010
Harding, J. L., Shaw, J. E., Peeters, A., Guiver, T., Davidson, S., & Magliano, D. J. (2014) · Diabetes Care · doi:10.2337/dc14-0096 · Cited by 158
Crujeiras, A. B., Díaz‐Lagares, Á., Carreira, M. C., Amil, M., & Casanueva, F. F. (2013) · Free Radical Research · doi:10.3109/10715762.2013.772604 · Cited by 135
Diabetes and cancer: Associations, mechanisms, and implications for medical practice
Xu, C. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i3.372 · Cited by 138
Charvat, H., Goto, A., Goto, M., Inoue, M., Heianza, Y., Arase, Y., Sone, H., Nakagami, T., Song, X., Qiao, Q., et al. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12333 · Cited by 133
Body mass index in childhood and adult risk of primary liver cancer
Berentzen, T. L., Gamborg, M., Holst, C., Sørensen, T. I. A., & Baker, J. L. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.09.015 · Cited by 138
Chronic inflammation and cancer; the two sides of a coin
Fernandes, Q., Inchakalody, V. P., Bedhiafi, T., Mestiri, S., Taib, N., Shahab Uddin, M. S., Merhi, M., & Dermime, S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122390 · Cited by 143
Hu, C.-M., Tien, S.-C., Hsieh, P.-K., Jeng, Y.-M., Chang, M.-C., Chang, Y.-T., Chen, Y.-J., Chen, Y.-J., Lee, E. Y.-H. P., & Lee, W.-H. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.005 · Cited by 123
Habib, S. L., & Rojna, M. (2013) · ISRN Oncology · doi:10.1155/2013/583786 · Cited by 131
Defining the pathway to insulin-like growth factor system targeting in cancer
Rosenzweig, S. A., & Atreya, H. S. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.06.013 · Cited by 127
Imbalance of angiogenesis in diabetic complications: The mechanisms
Tahergorabi, Z., & Khazaei, M. (2012) · International Journal of Preventive Medicine · doi:10.4103/2008-7802.104853 · Cited by 132
Tang, G. H., Satkunam, M., Pond, G. R., Steinberg, G. R., Blandino, G., Schünemann, H. J., & Muti, P. (2018) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0936 · Cited by 117
Diabetes and cancer I: risk, survival, and implications for screening
Onitilo, A. A., Engel, J. M., Glurich, I., Stankowski, R. V., Williams, G. M., & Doi, S. A. R. (2012) · Cancer Causes & Control · doi:10.1007/s10552-012-9972-3 · Cited by 127
Diabetes and Risk of Prostate Cancer
Tseng, C. (2011) · Diabetes Care · doi:10.2337/dc10-1640 · Cited by 123
Dual IGF-I/II–Neutralizing Antibody MEDI-573 Potently Inhibits IGF Signaling and Tumor Growth
Gao, J., Chesebrough, J. W., Cartlidge, S. A., Ricketts, S., Incognito, L., Veldman-Jones, M. H., Blakey, D. C., Tabrizi, M. A., Jallal, B., Trail, P. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2274 · Cited by 124
van Staa, T. P., Patel, D., Gallagher, A. M., & Bruin, M. L. D. (2011) · Diabetologia · doi:10.1007/s00125-011-2390-3 · Cited by 121
“Decreased rates of prostate cancer and NMSC have been reported in the literature [12, 13] and also found in the present study.”
ResultPhoomak, C., Vaeteewoottacharn, K., Silsirivanit, A., Saengboonmee, C., Seubwai, W., Sawanyawisuth, K., Wongkham, C., & Wongkham, S. (2017) · Scientific Reports · doi:10.1038/srep43842 · Cited by 122
Diabetes and Cancer: Is Diabetes Causally Related to Cancer?
Suh, S., & Kim, K. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.3.193 · Cited by 122
Metadata
- Authors
- Vigneri, P., Frasca, F., Sciacca, L., Pandini, G., & Vigneri, R.
- Affiliations
- Section of General Pathology 1
- University of Catania (IT)
- Corresponding author
- Vigneri, Paolo
- Venue
- Endocrine Related Cancer
- Publisher
- Bioscientifica
- Published
- 2009-12-01
- Volume
- 16
- Issue
- 4
- Pages
- 1103-1123
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2163691729
- Cited by
- 1,009
- References
- 183
- Citations by year
- 2026: 20 · 2025: 43 · 2024: 54 · 2023: 49 · 2022: 49 · 2021: 46 · 2020: 50 · 2019: 57 · 2018: 60 · 2017: 75 · 2016: 59 · 2015: 68 · 2014: 85 · 2013: 97 · 2012: 80
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrine Related Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Associazione Italiana per la Ricerca sul Cancro
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- diabetes mellitus, cancer risk, hyperinsulinemia, insulin-like growth factor I, insulin receptor, metformin, antidiabetic drugs, glucocorticoids, androgen receptor antagonists, obesity, hyperglycemia, oxidative stress, pancreatic cancer, liver cancer, breast cancer, colorectal cancer, cancer mortality, confounding factors
- MeSH terms
- Humans, Neoplasms, Risk Factors, Survival Rate, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
